Claritas Genomics Appoints Patrick F. Terry As Chief Commercial Officer

CAMBRIDGE, Mass., Dec. 18, 2014 /PRNewswire/ -- Claritas Genomics today announced the appointment of Patrick F. Terry to the role of Chief Commercial Officer. Mr. Terry, Chairman, Gray Group Ventures Ltd., and a founder of Genomic Health, Inc. [NASDAQ: GHDX], has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery.  Mr. Terry will build Claritas's commercial organization to expand the company's reach to pediatric hospitals and patients and ensure that the Claritas services also meet the needs of payers.  He will report to Claritas's President and Chief Executive Officer Patrice Milos, Ph.D.

Patrick Terry, Chief Commercial Officer, Claritas Genomics
Mr. Terry's involvement with the genomics community began in 1994 when both of his children were diagnosed with pseudoxanthoma elasticum (PXE), a genetic disease.  He and his wife, Sharon, founded PXE International to accelerate research into the rare condition.  Terry, who ran a general contracting firm at the time, became the first layperson to patent a human disease gene, the gene that causes PXE. 

"Patrick Terry brings an unprecedented range of research and commercialization expertise to Claritas," says Patrice Milos, Ph.D, Claritas Genomics president and CEO. "This, combined with his personal experience as a patient advocate, makes him an extraordinary fit for Claritas, where our mission encompasses helping patients and families by making connections between genomic experts around the world, between next-generation technologies, and between healthcare providers, patients and the advocacy community."

Mr. Terry has co-founded and advised multiple life science ventures, including two applied genetics companies, and participated in securing over $600 million dollars in financing. He brings extensive experience in pricing, reimbursement and market access practice strategies in the Americas, Europe, Asia and emerging economies.

"I joined Claritas Genomics because of the many convergences between their mission and my personal passion and family experiences," says Patrick F. Terry. "Together, we can extend the power of the human genome to advance health and alleviate suffering for patients and their families."

Claritas Genomics, affiliated with Boston Children's Hospital, is a CLIA-certified laboratory performing genetic diagnostic testing services for the pediatric community and research sequencing to support the research community.  Claritas has developed over one hundred validated clinical tests for single genes associated with pediatric disorders as well as dynamic, whole exome-based tests. Claritas has broken new ground in the rapidly evolving field of exome-based testing, introducing tests that deliver a focused analysis to enhance detection rates.

After founding PXE International, Terry was a Principal with Scientia Advisors Inc. and co-founded the Personalized Medicine Coalition, European Personalized Medicine Association, and the International Genetic Alliance, He has held numerous national and international leadership positions and has published extensively in the fields of genetics, personalized medicine, and biomedical research. 

About Claritas Genomics         
Claritas Genomics is a clinical genetic diagnostic testing company that combines the clinical expertise of the world's best pediatric specialists with next generation sequencing technology to inform and improve patient care. Claritas offers a full range of services that take the guesswork out of selecting molecular tests and support clinicians as they navigate the increasingly complex landscape of genetic diagnostics. Claritas's interpretive services are based on the most up to date and reliable findings and the Claritas reports are designed to clearly communicate complex genetic information to guide medical treatment. Originally Boston Children's Hospital's clinical molecular testing laboratory, Claritas was launched as an independent laboratory in 2013.  Learn more about Claritas Genomics at

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.